Chemomab Therapeutics’ (CMMB) “Outperform” Rating Reiterated at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Chemomab Therapeutics (NASDAQ:CMMB) in a report published on Friday morning,Benzinga reports. Oppenheimer currently has a $11.00 price objective on the stock, down from their previous price objective of $13.00.

Chemomab Therapeutics Stock Down 1.5 %

Chemomab Therapeutics stock opened at $1.65 on Friday. The firm has a market capitalization of $23.69 million, a PE ratio of -1.65 and a beta of 0.53. Chemomab Therapeutics has a 52 week low of $0.42 and a 52 week high of $2.55. The firm’s 50-day simple moving average is $1.55 and its 200 day simple moving average is $1.29.

Chemomab Therapeutics (NASDAQ:CMMB) last released its quarterly earnings results on Wednesday, August 21st. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). During the same quarter last year, the business posted ($0.72) EPS. On average, research analysts expect that Chemomab Therapeutics will post -0.9 EPS for the current fiscal year.

Institutional Trading of Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. bought a new stake in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned approximately 8.46% of Chemomab Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).